news
Equinox Executive Chair Backs Vesalius Longevity Labs in $6.5M Round
Equinox executive chairman Harvey Spevak led a $6.5 million financing round for Vesalius Longevity Labs. The publicly traded longevity company supplies prescription peptides, biomarker panels, and physician-supervised protocols across a growing clinical network. The move signals how quickly luxury gym operators are tying workout floors to injectable therapeutics.
Equinox executive chairman Harvey Spevak led a $6.5 million financing round for Vesalius Longevity Labs. The publicly traded longevity company supplies prescription peptides, biomarker panels, and physician-supervised protocols across a growing clinical network. The move signals how quickly luxury gym operators are tying workout floors to injectable therapeutics.
The architecture take
Luxury fitness stopped caring about six-pack abs roughly eighteen months ago, and this deal shows where the real money is going. Vesalius Longevity Labs builds out clinical networks delivering targeted peptides, hormone optimization, and biomarker testing to people who already pay $300 a month just to shower in eucalyptus mist. When the executive chairman of Equinox puts $6.5 million behind a prescription peptide outfit, it tells you the gym floor is quietly becoming the waiting room for regenerative medicine.
I used to think the jump from deadlifts to subcutaneous injections would scare off casual lifters. That calculation was wrong. It turns out people are eager to bypass standard clinical gatekeepers if an upscale provider packages BPC-157 or growth hormone secretagogues as routine recovery. The play here is vertical integration: track your biological age in the club, then sell you the protocol to nudge the mitochondria down in the lab. Watch how quickly other high-end health clubs follow with their own medical director tie-ins by autumn.